SynAct Pharma AB, a Swedish listed biotechnology company (Nasdaq Stockholm: SYNACT), acquires 100% of TXP Pharma AG, a privately owned Swiss biotech company, researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. BGPartner assisted SynAct Pharma AB in the negotiations and advised on all Swiss legal matters regarding this international M&A transaction.
Through the acquisition of TXP Pharma AG, SynAct Pharma AB’s position as a leader within therapies for resolution treatment through melanocortin biology is strengthened. The acquisition gives SynAct Pharma AB two platforms that complement each other and create a versatility to develop therapies to address the full range of inflammatory and autoimmune diseases. The development portfolio is strengthened, and the aim is that SynAct Pharma AB will shortly have two projects in clinical development and another two in a relatively advanced preclinical phase.
The purchase price consisted of a fixed purchase price of approximately SEK 136 million (approximate CHF 12 million) and a conditional additional purchase price of SEK 55 million (approximate CHF 5 million). The fixed purchase price has been paid through newly issued shares in SynAct Pharma AB.
The team of BGPartner was led by Oliver Gnehm (Partner) and further consisted of Alain P. Röthlisberger (Partner) and Victoria Marty (Associate).
The press release of SynAct Pharma AB can be found here.
Authors:
Oliver Gnehm, Dr. Alain P. Röthlisberger, Victoria Marty
gnehm@bgpartner.ch
+41 31 329 55 55
BGPartner Ltd
